Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Tetracaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.82 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.82 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.82 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.82 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.82 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.82 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 5/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.82 |
| ▸ | MAOA | P21397 | 3/20 | 0.82 |
| ▸ | DRD3 | P35462 | 2/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.82 |
| ▸ | CNR1 | P21554 | 1/20 | 0.82 |
| ▸ | DRD4 | P21917 | 1/20 | 0.82 |
| ▸ | ACHE | P22303 | 1/20 | 0.82 |
| ▸ | HRH2 | P25021 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.82 |
| ▸ | HTR2C | P28335 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetracaine SCHEMBL1429149 | 0.91 | LMNA (0.79) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL34714 | 0.91 | LMNA (1.00) | LMNACYP1A2MAOASCN5ADRD3 | |
| Butacaine SCHEMBL2161574 | 0.90 | LMNA (0.77) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL3176478 | 0.90 | LMNA (0.97) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL27896875 | 0.90 | LMNA (0.97) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL7774179 | 0.90 | LMNA (0.97) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL24370 | 0.90 | LMNA (1.00) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL28641231 | 0.90 | LMNA (0.97) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL1355595 | 0.90 | LMNA (1.00) | LMNACYP1A2MAOASCN5ADRD3 | |
| Tetracaine SCHEMBL2728732 | 0.88 | LMNA (0.95) | LMNACYP1A2MAOASCN5ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20100113426-A1 | Intranasal Benzodiazepine Compositions | WERMELING DANIEL P | 2010-05-06 | — | — | US | disclosed |
| EP-1727549-A4 | INTRANASAL BENZODIAZEPINE COMPOSITIONS | UNIV KENTUCKY RES FOUND (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070110689-A1 | Oral anaesthetic gel | FELDSCHUH MARK | 2007-05-17 | — | — | US | disclosed |
| US-20070071687-A1 | INTRANASAL BENZODIAZEPINE COMPOSITIONS | WERMELING DANIEL P | 2007-03-29 | — | — | US | disclosed |
| EP-1727549-A1 | INTRANASAL BENZODIAZEPINE COMPOSITIONS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1708668-A1 | ORAL ANAESTHETIC GEL | Oral Bioscience Pty. Limited (AU) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005089768-A1 | INTRANASAL BENZODIAZEPINE COMPOSITIONS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005067865-A1 | ORAL ANAESTHETIC GEL | ORAL BIOSCIENCE PTY. LIMITED (AU) | 2005-07-28 | — | — | WO | disclosed |
| US-20040176359-A1 | Intranasal Benzodiazepine compositions | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2004-09-09 | — | — | US | disclosed |
| EP-0831774-B1 | ORAL DOSAGE AND METHOD FOR TREATING PAINFUL CONDITIONS OF THE ORAL CAVITY | ALZA CORP (US) | 2001-07-11 | — | — | EP | disclosed |
| US-5713852-A | Oral dosage and method for treating painful conditions of the oral cavity | ALZA CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| CN-1016760-B | Anaphylaxis test device | FISHER TORKEL INGEMAR (SE) | 1992-05-27 | — | — | CN | disclosed |
| CN-85107871-A | Anaphylaxis test device | — | 1986-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176359-A1 | Intranasal Benzodiazepine compositions | GABRA1, GABRA2, GABRA6 | SCN5A 204/4885SCN1A 49/4885SCN2A 92/4885 |
| US-20100113426-A1 | Intranasal Benzodiazepine Compositions | GABRA1, GABRA2, GABRA6 | SCN5A 204/4885SCN1A 49/4885SCN2A 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.